Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Mes dernières consult.
Most popular
Analysis summary4-Traders Strategies

Anaïs Lozach

share with twitter share with LinkedIn share with facebook
share via e-mail

Hesitation should subside in favor of volatility

Strategy published on 04/28/2017 | 15:18
long trade
Stop-loss triggered
Entry price : 124.21$ | Target : 129$ | Stop-loss : 121.7$ | Potential : 3.86%
The price of Celgene Corporation shares is range-bound. This phase will end sooner or later when volatility comes back.
Investors have an opportunity to buy the stock and target the $ 129.
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

  • Its core activity has a significant growth potential and sales are expected to surge, according to Thomson Reuters' forecast. Indeed, those may increase by 59% by 2019.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 112.66 USD

  • Stock prices approach a strong long-term resistance in weekly data at USD 125.77.
  • The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials ($)
Sales 2018 14 804 M
EBIT 2018 8 491 M
Net income 2018 5 280 M
Debt 2018 274 M
Yield 2018 -
P/E ratio 2018 12,94
P/E ratio 2019 10,83
EV / Sales 2018 4,51x
EV / Sales 2019 3,62x
Capitalization 66 425 M
Surperformance© ratings
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Earnings quality
Business Predictability
P/E ratio
Yield -
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
Bollinger Spread
Unusual Volumes
Duration : Period : Day
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Duration : Period : Week
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders